brand-logo

Welcoming our new Business Planning and Analysis Manager

Welcoming our new Business Planning and Analysis Manager

 

Accelagen is delighted to announce David Stella as our new Business Planning and Analysis Manager. With over a decade of experience in financial planning and analysis, David joins us from IDP Education, an ASX top 100 company, where he excelled in financial reporting and business analysis.

 

Known for his ability to turn complex financial data into actionable insights that drive business growth and efficiency, David’s extensive expertise in financial systems and modelling makes him a perfect fit for Accelagen.

Since joining Accelagen mid-way through 2023, David has already made significant contributions to our rapid growth and has been instrumental in enhancing our world-leading work. His role focuses on developing and implementing financial management and forecasting strategies, streamlining processes for maximum efficiency. David also leads in delivering profitability reporting, financial modelling, and senior leadership team reporting, bringing a new level of precision to our financial management.

 

David’s passion for the health sector is evident, and he is dedicated to providing the data necessary for informed decision-making and amplifying Accelagen’s impact in the industry.

 

Outside work, David is a health and fitness enthusiast, enjoying morning jogs and bike rides. His love for travel and exploring new cultures reflects his openness to new experiences.

Accelagen is thrilled to have David on board. With the ideal blend of professional expertise and personal commitment, we look forward to his continued impact in shaping the future of Accelagen.

You might also like...​

You might also like...​

Welcoming our new Business Planning and Analysis Manager

Welcoming our new Business Planning and Analysis Manager   Accelagen is delighted to announce David Stella as our new Business Planning and Analysis Manager. With over a decade of experience in financial planning and analysis, David joins us from IDP Education, an ASX top 100 company, where he excelled in financial reporting and business analysis. […]

Read More
Hands operating syringe
Accelagen accelerates time to market for European clients: Potentially best-in-class study for Treatment of BKV Infection sees exciting results

Accelagen accelerates time to market for European clients: Potentially best-in-class study for Treatment of BKV Infection sees exciting results Local CRO, Accelagen, attracts innovative European drug and antibody developers to trial in Australian market Engaged by world-renowned European clients and collaborators, Memo Therapeutics AG (“MTx”) based in Switzerland, and Vakzine Projekt Management GmbH (VPM) based […]

Read More
Amritha
Accelagen Staff Announcement: Amritha Vangur

Accelagen Staff Announcement: Amritha Vangur The Accelagen family is growing…again! Today we are thrilled to announce that Amritha Vangur has rejoined our team as Clinical Research Associate. Amritha first worked at Accelagen in 2019. The company was in its infancy at the time, with a small, tight-knit team. Shortly after joining, Amritha travelled overseas and […]

Read More